# EDGAR Filing Document

**Accession Number:** 0001917375
**File Stem:** 0000000000-23-001326
**Filing Date:** 2023-2
**Character Count:** 4084
**Document Hash:** c3dc001e28569945c04f39061d98be5f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001326.hdr.sgml**: 20230418

**ACCESSION NUMBER**: 0000000000-23-001326

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230208

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ONCOLYZE, INC.
- **CENTRAL INDEX KEY:** 0001917375
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 845 UN PLAZA, APT. 61B
- **STREET 2:** ATTN: STEVEN J. EVANS, M.D.
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 917-670-5933

**MAIL ADDRESS:**
- **STREET 1:** 845 UN PLAZA, APT. 61B
- **STREET 2:** ATTN: STEVEN J. EVANS, M.D.
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001104659-23-009998

## Text-Extract

```

United States securities and exchange commission logo

                           February 8, 2023

       Steven J. Evans, MD
       Chief Executive Officer
       Oncolyze, Inc.
       845 UN Plaza, 61b
       New York, NY 10017

                                                        Re: Oncolyze, Inc.
                                                            Post-Qualification
Amendment to Offering Statement on Form 1-A
                                                            Filed on February
2, 2023
                                                            Post-Qualification
Amendment to Offering Statement on Form 1-A
                                                            Filed February 6,
2023
                                                            File No. 024-11890

       Dear Steven J. Evans:

                                                        This is to advise you
that we do not intend to review your amendments.

               We will consider qualifying your offering statement at your
request. If a participant in
       your offering is required to clear its compensation arrangements with
FINRA, please have
       FINRA advise us that it has no objections to the compensation
arrangements prior to
       qualification.

               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff.

                                                        Please contact Joshua
Gorsky at 202-551-7836 with any questions.

                           Sincerely,

                           Division of Corporation Finance

                           Office of Life Sciences
       cc:                                              Jeanne Campanelli

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 8, 2023

Steven J. Evans, MD
Chief Executive Officer
Oncolyze, Inc.
845 UN Plaza, 61b
New York, NY 10017

Re: Oncolyze, Inc.

Post-Qualification Amendment to Offering Statement on Form 1-A

Filed on February 2, 2023

Post-Qualification Amendment to Offering Statement on Form 1-A

Filed February 6, 2023

File No. 024-11890

Dear Steven J. Evans:

This is to advise you that we do not intend to review your amendments.

We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Joshua Gorsky at 202-551-7836 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Jeanne Campanelli